Editor’s Note
Amorepacific Holdings has signed an investment agreement with HIER Corporation, a skin beauty medical device specialist, to bolster collaboration across the beauty and medical sectors. Founded in 2021, HIER develops and distributes aesthetic devices, including its flagship collagen booster “HiloWave,” which uses dual hyaluronic acid technology.
By Kwon Yoo-jeong
Published 2026.07.27. 15:32
Updated 2026.07.27. 15:33
Amorepacific Holdings (002790) announced on the 27th that it has signed an investment agreement with HIER Corporation, a company specializing in skin beauty medical devices, to strengthen cooperation in the beauty and medical sectors.
HIER Corporation is a company specializing in skin beauty medical devices founded in 2021. It develops and distributes aesthetic medical devices, and its flagship product is the collagen booster “HiloWave,” based on dual hyaluronic acid (Dual-HA).
/Courtesy of Amorepacific
Under this agreement, the two companies will combine HIER Corporation’s capabilities in developing aesthetic medical devices and its medical professional network with Amorepacific’s skin science research and skincare technology to collaborate on product planning, research and development (R&D), distribution, and marketing. Amorepacific Holdings also made a strategic investment in HIER Corporation as part of this agreement.
The two companies will push the development and commercialization of skin boosters, cosmeceuticals, and medical devices related to skin beauty. They also plan to jointly develop post-procedure aftercare products, cooperate on distribution to hospitals and clinics, and conduct joint research and development on ingredients and materials, as well as marketing.
In particular, based on HIER Corporation’s medical professional network and expertise in the aesthetic market and Amorepacific’s skin research capabilities, they plan to develop an integrated solution that connects professional procedures with everyday skincare.
— Lee Sang-mok, CEO of Amorepacific Holdings
※ This article has been translated by AI. Share your feedback here.
View Original Article (Korean)
Kwon Yoo-jeong Staff writer, Business & Tech News Desk